Windtree Therapeutics (WINT) announced that the United States Patent and Trademark Office has issued a Notice of Allowance for U.S. application number 18/150,870 directed to “ISTAROXIME-CONTAINING INTRAVENOUS FORMULATION FOR THE TREATMENT OF ACUTE HEART FAILURE.”
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WINT:
- Windtree Therapeutics files patent in India for cardiac arrythmia therapy
- Windtree Therapeutics Inc trading halted, news pending
- Windtree Therapeutics Announces Reverse Stock Split Approval
- Windtree Therapeutics board approves 1-for-50 reverse stock split
- Windtree Therapeutics files to sell 40M shares of common stock for holders
Looking for a trading platform? Check out TipRanks' Best Online Brokers , and find the ideal broker for your trades.
Report an Issue